Featured Story

  • RainDance waltzes toward $60M IPO

    RainDance Technologies is moving one step closer to completing its long-awaited IPO, filing plans for a $60 million offering to cash in on a growing market for its next-generation sequencing tools.

Navidea joins forces with Norgine to market cancer imaging Dx in EU

Navidea Biopharmaceuticals is teaming up with European specialty pharma company Norgine to commercialize its Lymphoseek cancer diagnostic aid in Europe, looking to make a market splash as it drives international growth.

OpGen eyes IPO worth up to $37M for drug-resistant bacteria genetic Dx

Microbial genetics analysis outfit OpGen is inching one step closer to an initial public offering, planning to raise up to $37 million for its genetic screening technologies for drug-resistant bacteria.

FDA grants emergency use authorization to Corgenix's fast-acting Ebola diagnostic

"This thing isn't over yet," warned President Barack Obama's Ebola czar Ron Klain in a recent interview. While recovering slowly West Africa is plagued by the epidemic and needs new tools in the ongoing battle against the disease.

Illumina Accelerator gets $40M boost from Viking Global

Illumina's new business accelerator, Illumina Accelerator Boost Capital, got a $40 million cash infusion from hedge fund Viking Global Investors. Illumina Accelerator will use the cash to fund investments in promising genomic startups, spurring innovation and providing dollar-for-dollar matching funds for every graduate company that raises between $1 million and $5 million during the funding cycle.

Skin test could vastly simplify diagnosis of Alzheimer's and Parkinson's

Researchers have discovered that a skin sample taken from behind the ear of patients with either Alzheimer's or Parkinson's disease had levels of the protein tau 7 times higher than those without the condition. Those with Parkinson's showed levels of alpha-synuclein protein that were 8 times higher than those in the control group.